AI English summary of an SEC filing — figures as filed
Regeneron Pharmaceuticals REGNRegeneron said Sanofi will make an upfront payment of $1.0 billion to it under the Sixth Amendment, and that it will be entitled to receive up to an additional $7.0 billion in aggregate milestone payments tied to the New Licensed Products.
Key points
AI summaryRegeneron said Sanofi will make an upfront payment of $1.0 billion to it under the Sixth Amendment, and that it will be entitled to receive up to an additional $7.0 billion in aggregate milestone payments tied to the New Licensed Products.
Sanofi and Regeneron entered into the Sixth Amendment on October 1, 2026, and the company said they agreed to co-develop and co-commercialize 4 long-acting, Regeneron-invented antibodies, including an IL-IL-13 antibody, an IL-IL-4 antibody, an IL-IL-4RRα antibody and an IL-IL-4xIL-13 bispecific antibody.
Regeneron said global profits from New Licensed Products will be shared equally with Sanofi, and development costs will also be shared equally. The company said it will bear development costs above the budget cap for all New Licensed Products. Sanofi will lead commercialization of the New Licensed Products.
The company said it expects its GAAP and non-GAAP results for Q3 2026 to include an acquired IPR&D charge of approximately $22 million on a pre-tax basis. It said the charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share by approximately $0.18. These figures are unaudited preliminary estimates that are subject to the closing procedures for financial statements.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Sanofi Upfront Payment of $1.0 billion and Up to $7.0 billion in Milestones
Regeneron said Sanofi will make an upfront payment of $1.0 billion to it under the Sixth Amendment, and that it will be entitled to receive up to an additional $7.0 billion in aggregate milestone payments tied to the New Licensed Products.
Source · Based on the filing body and exhibits
Co-Development and Co-Commercialization of 4 New Long-Acting Antibodies
Sanofi and Regeneron entered into the Sixth Amendment on October 1, 2026, and the company said they agreed to co-develop and co-commercialize 4 long-acting, Regeneron-invented antibodies, including an IL-IL-13 antibody, an IL-IL-4 antibody, an IL-IL-4RRα antibody and an IL-IL-4xIL-13 bispecific antibody.
Source · Based on the filing body and exhibits
Equal Profit Sharing, Development Cost Split and Lead Roles
Regeneron said global profits from New Licensed Products will be shared equally with Sanofi, and development costs will also be shared equally. The company said it will bear development costs above the budget cap for all New Licensed Products. Sanofi will lead commercialization of the New Licensed Products.
Source · Based on the filing body and exhibits
Acquired IPR&D Charge of About $22 million Expected for Q3 2026
The company said it expects its GAAP and non-GAAP results for Q3 2026 to include an acquired IPR&D charge of approximately $22 million on a pre-tax basis. It said the charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share by approximately $0.18. These figures are unaudited preliminary estimates that are subject to the closing procedures for financial statements.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…